Yusha Zakai, MD
Endocrinology, Diabetes & Metabolism · Griffin, GANPI 1063806446
Payments from drug & device makers
Across 183 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$401
- Novo Nordisk$351
- Insulet Corporation$347
- Corcept Therapeutics$268
- Mannkind Corporation$239
- Lilly USA, LLC$224
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,724100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 20 | $401 |
| Novo Nordisk | 17 | $351 |
| Insulet Corporation | 19 | $347 |
| Corcept Therapeutics | 12 | $268 |
| Mannkind Corporation | 9 | $239 |
| Lilly USA, LLC | 11 | $224 |
| Tandem Diabetes Care, Inc. | 11 | $215 |
| Amgen(2 entities) | 9 | $163 |
| Sanofi-aventis U.S. LLC | 7 | $148 |
| Radius Health, Inc. | 6 | $139 |
| BETA Bionics, Inc. | 2 | $126 |
| Abbott | 7 | $113 |
| Boehringer Ingelheim | 5 | $103 |
| Dexcom, Inc. | 6 | $100 |
| Sequel Med Tech, LLC | 3 | $90 |
| Xeris Pharmaceuticals, Inc. | 4 | $83 |
| Esperion Therapeutics, Inc. | 3 | $66 |
| Medtronic(2 entities) | 4 | $64 |
| Merck | 4 | $63 |
| AbbVie | 3 | $53 |
| Antares Pharma, Inc. | 2 | $38 |
| Recordati_rare_diseases_inc. | 2 | $37 |
| Ascendis Pharma Endocrinology Inc | 2 | $35 |
| Viiv Healthcare Company | 1 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $28 |
| Bayer | 2 | $26 |
| IBSA Pharma Inc. | 1 | $21 |
| Neuros Medical, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| EUSA Pharma (US) LLC | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Almatica Pharma LLC | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Cequr Corporation | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$312
- FARXIGA$125
How this compares
$3,724 in reported general payments places this provider in the 50th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 344 | $431,526 |
| MounjaroTirzepatide | 151 | $198,496 |
| JardianceEmpagliflozin | 153 | $178,690 |
| TrulicityDulaglutide | 66 | $99,406 |
| FarxigaDapagliflozin Propanediol | 84 | $86,409 |
| Tresiba Flextouch U-100Insulin Degludec | 96 | $67,979 |
| Tresiba Flextouch U-200Insulin Degludec | 56 | $49,998 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $32,000 |
| ProliaDenosumab | 17 | $29,732 |
| RybelsusSemaglutide | 20 | $27,342 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 24 | $25,362 |
| Novolog FlexpenInsulin Aspart | 56 | $14,768 |
| TradjentaLinagliptin | 12 | $13,138 |
| Humalog Kwikpen U-100Insulin Lispro | 33 | $12,002 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $11,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $351 | $458,868364 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $224 | $303,180231 claims |
| Boehringer IngelheimJardiance, Tradjenta | $103 | $191,828165 claims |
| AstraZenecaFarxiga | $401 | $86,40984 claims |
| AmgenProlia | $163 | $29,73217 claims |
| AbbVieSynthroid | $53 | $4,02554 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $28 | $1,879177 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Griffin
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- John ReedRoswell$5.7M
- Thomas JonesMacon$4.8M
- Steven LeichterColumbus$3.1M
- Jason BernerJasper$2.6M
- Ashwini GoreMacon$2.6M
- Adeniyi OdugbesanLawrenceville$1.8M
- David RobertsonAtlanta$1.7M
- Thomas ZieglerAtlanta$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.